Kim Chi, ASCO GU22: First Results of the Phase III MAGNITUDE Study
Dr Kim Chi (The University of British Columbia, Vancouver, BC, Canada) summarises the first results of the phase 3 MAGNITUDE (NCT03748641) study of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without homologous recombination repair gene alterations.
- What is known about the combination of PARP inhibitors and abiraterone acetate plus prednisone in the treatment of patients with metastatic prostate cancer? (00:17-01:40)
- What were the aims, design and inclusion criteria of the MAGNITUDE study? (01:40-03:13)
- What were the efficacy and safety findings of the study and how did they differ in the cohorts with and without DNA repair defects? (03:14-06:09)
- What will be the challenges of incorporating PARP inhibitors into clinical practice in this patient population? (06:09-07:36)
Speaker Disclosure: Kim Chi discloses consultancy services for: Astellas, AstraZeneca, Daiichi Sankyo, Janssen, Macrogenics, Merck, Novartis, Pfizer, Point Biopharma, Roche and Sanofi. He discloses grant/research support from: Astellas, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche and Sanofi. He is a member of the advisory board for: Astellas, Astra Zeneca, Janssen, Merck, Novartis and Roche. He has received honoraria/honorarium from: AstraZeneca, Janssen and Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Genitourinary Cancers Symposium 2022
Share this Video
Related Videos In Genitourinary Cancer
Sebastian Schmid, ESMO 2022: RACE-IT – RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in advanced bladder cancer
Patients with locally advanced bladder cancer have a poor prognosis despite surgical therapy. Prof. Sebastian Schmid (Technical University of Munich, Munich, Germany) joins touchONCOLOGY to discuss the unmet needs in the treatment of locally advanced bladder cancer, and also discusses the feasibility, safety and efficacy of neoadjuvant radio-immunotherapy following radical cystectomy in patients with locally […]
Jonathan Rosenberg, ESMO 2022: Study EV-103 Cohort K – Enfortumab vedotin in combination with pembrolizumab in locally advanced or metastatic urothelial cancer
As there is a current need for effective and tolerable first line treatment options in patients with locally advanced or metastatic urothelial cancer (la/mUC), Dr Jonathan Rosenberg (Memorial Sloan Kettering Cancer Center, New York, NY, USA) joins touchONCOLOGY to discuss the positive results from Study EV-103 Cohort K. The study data supports ongoing investigations of […]
Enrique Grande, ESMO 2022: Post-hoc analysis investigating PD-L1 expression on immune cells, and improved OS with atezolizumab in patients with urothelial cancer
PD-L1 assays use various methods to predict PD-L1/PD-1 blockade outcomes, recent data suggests clinically relevant PD-L1–expressing immune cells are dendritic cells. Dr Enrique Grande Pulido (MD Anderson Cancer Centre Madrid, Madrid, Spain) joins touchONCOLOGY to discuss a post-hoc analysis investigating PD-L1 expression on immune cells by SP142 co-localises with dendritic cells, and the associated improved overall […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!